Stryker Corporation $SYK Shares Bought by Argent Trust Co

Argent Trust Co grew its stake in Stryker Corporation (NYSE:SYK - Free Report) by 66.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,889 shares of the medical technology company's stock after purchasing an additional 6,339 shares during the quarter. Argent Trust Co's holdings in Stryker were worth $5,002,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new stake in Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker during the fourth quarter worth $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker during the fourth quarter worth $28,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK stock opened at $338.80 on Monday. The business has a fifty day moving average of $324.61 and a two-hundred day moving average of $333.40. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $129.95 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Wells Fargo & Company dropped their price target on Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research report on Friday, May 1st. Piper Sandler cut their price target on Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Raymond James Financial set a $370.00 price objective on Stryker in a research report on Friday, July 31st. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 310,000 shares of the business's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company's stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source